CRVS
Corvus Pharmaceuticals Inc

6,135
Mkt Cap
$509.33M
Volume
292,356.00
52W High
$9.60
52W Low
$2.54
PE Ratio
-12.75
CRVS Fundamentals
Price
$7.06
Prev Close
$6.82
Open
$6.81
50D MA
$7.96
Beta
1.56
Avg. Volume
1.63M
EPS (Annual)
-$1.02
P/B
7.10
Rev/Employee
$0.00
News
all
press releases
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Still a Buy?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Should You Buy...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% - Should You Sell?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 6.5% - Time to Sell...
MarketBeat·13d ago
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. One...
MarketBeat·19d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Up 3.5% - Still a Buy...
MarketBeat·20d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% Higher - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Here's What Happened
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Should You Buy...
MarketBeat·1mo ago
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS
Foresite Capital Management VI LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 9.5% in the 2nd quarter, according to its most recent disclosure with...
MarketBeat·2mo ago
News Placeholder
BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS
BML Capital Management LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·2mo ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 7.4% - Still a Buy?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.4% Higher - What's Next...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.